Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Epilepsy × enzalutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15 Prostatic Neoplasms, Castration-Resistant 3 Non-metastatic Castration-resistant Prostate Cancer 2 Neoplasm Metastasis 2 Metastatic Castration Resistant Prostate Cancer 2 Sleep Initiation and Maintenance Disorders 1 Metastatic Hormone-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Fatigue 1 Epilepsy 1 Depression 1 Castration-resistant Prostate Cancer 1 Brain Diseases 1 Advanced Prostate Carcinoma 1

Interventions

ziprasidone 1 enzalutamide 1 Zolpidem 1 Warfarin 1 Vecuronium Bromide 1 Vancomycin 1 Tranexamic Acid 1 Tobramycin 1 Surgical Procedures, Operative 1 Spironolactone 1 Sevelamer 1 Rocuronium 1 Registries 1 Piperacillin, Tazobactam Drug Combination 1 Pentobarbital 1 Oxycodone 1 Nifedipine 1 Neuropsychological Tests 1 Nafcillin 1 Molindone 1 Methylprednisolone 1 Medical Marijuana 1 Mass Screening 1 Magnetoencephalography 1 Lurasidone Hydrochloride 1 Labetalol 1 Histocompatibility Testing 1 Haloperidol 1 Fosfomycin 1 Clozapine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04290611 2023-04-13

VENDY

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Brain Diseases, Epilepsy, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡